|
About the presentation
Evotec has developed an innovative and exciting clinical CNS pipeline. This includes the NR2B subtype selective NMDA receptor antagonists, EVT 101 and EVT 103, which have potential in a number of CNS indications, including treatment resistant depression, Alzheimer’s disease, Huntington’s disease and pain. EVT 101 will shortly start a Phase II study in treatment resistant depression. Other clinical development programmes include EVT 302, a potent and selective MAO-B inhibitor with disease-modifying potential in Alzheimer’s disease, EVT 201, a novel GABAA-receptor partial positive allosteric modulator for the treatment of insomnia and EVT 401 a P2X7 antagonist with potential in a number of inflammatory conditions. |
|
About the speaker
Dr John A Kemp is Chief Research and Development Officer of Evotec. He joined the Company in July 2002 as CEO of Evotec Neurosciences GmbH (ENS). Prior to this he spent almost 20 years within the pharmaceutical industry, where he gained considerable experience in progressing projects from target initiation through to entry into the clinic. From the beginning of 2000 until joining ENS, John Kemp was Vice President and Head of CNS Research at Hoffmann-La Roche in Basel, Switzerland and prior to that he spent 6 years as Research Area Head for Neurodegenerative Diseases at Roche. Before joining Roche, John Kemp was at the Merck Sharp and Dohme, Neuroscience Research Centre in Harlow, UK, for almost 11 years, rising to the position of Section Leader for in vitro pharmacology. John Kemp trained as a Pharmacologist and Neuroscientist, obtaining his Ph.D. from the University of Southampton in 1979, and has published over 120 peer reviewed research papers in these disciplines. He is listed in the Pharmacology section of ISI’s most highly cited researchers. |
 |
